| Identification | Back Directory | [Name]
L-Alaninamide, N-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1,6-dioxohexyl]-L-alanyl-N-[3-[[[(12aS)-12a,13-dihydro-8-methoxy-6-oxo-6H-indolo[2,1-c][1,4]benzodiazepin-9-yl]oxy]methyl]-5-[[[(12aS)-11,12,12a,13-tetrahydro-8-methoxy-6-oxo-6H-indolo[2,1-c][1,4]benzodiazepin-9-yl]oxy]methyl]phenyl]- | [CAS]
1884276-68-9 | [Synonyms]
DGN549-L
L-Alaninamide, N-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1,6-dioxohexyl]-L-alanyl-N-[3-[[[(12aS)-12a,13-dihydro-8-methoxy-6-oxo-6H-indolo[2,1-c][1,4]benzodiazepin-9-yl]oxy]methyl]-5-[[[(12aS)-11,12,12a,13-tetrahydro-8-methoxy-6-oxo-6H-indolo[2,1-c][1,4]benzodiazepin-9-yl]oxy]methyl]phenyl]- | [Molecular Formula]
C58H58N8O13 | [MOL File]
1884276-68-9.mol | [Molecular Weight]
1075.13 |
| Hazard Information | Back Directory | [Uses]
DGN549-L is a DNA alkylator and can be utilized for antibody conjugation at lysine residues. DGN549-L can be used in the synthesis of antibody-drug conjugates (ADCs)[1]. | [References]
[1] Bai C, et al. Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation. Bioconjug Chem. 2020;31(1):93-103. DOI:10.1021/acs.bioconjchem.9b00777 |
|
|